FDA Approves Expanded Age Indication for GARDASIL® 9 in Males

The U.S. Food and Drug Administration (FDA) approved an expanded age indication for GARDASIL®9, Merck’s 9-valent human papillomavirus (HPV) vaccine, to now include use in males 16 through 26 years of age.  “This is an important approval that now aligns the indication for GARDASIL 9 in males and females ages 9 through 26 to that of GARDASIL, and also supports the CDC’s HPV vaccine recommendations for use in males,” said Jacques Cholat, M.D., president, Merck Vaccines.

Please see the full Merck press release for more information.

Vaccine Storage Tips! Webinar Posted

If you were unable to join us for the Vaccine Storage Tips! webinar with Dr. Barden on November 18th, the recording has now been posted to the CPP website!  To access the webinar or the slides, simply go to the Vaccine Storage Resources section of the CPP website.  If you need the username and password to access the password protected resources, please contact the CPP office at cpp@nationwidechildrens.org.

Sanofi Pasteur Vaccine Updates

We wanted to make you aware of several updates regarding Sanofi Pasteur vaccines:

Customer End-of-Year Promotion – CPP Members will receive an additional 3% discount off of Menactra® and Adacel® doses ordered between now and Wednesday, December 16, 2015.  Orders must ship by Thursday, December 17, 2015.

Pentacel® Supply – Sanofi Pasteur is experiencing a manufacturing delay with Pentacel® and anticipates it will not be able to meet full demand throughout the first half of 2016.  In an effort to manage through this period, they are implementing customer level allocations – about 65%-85% of your monthly demand.  To help offset the gap in Pentacel® vaccine supply, Daptacel®, ActHIB®, and IPOL® will be be available at 125% of demand so that you have single-entity vaccines available to cover any pentacel shortage and maintain your immunization schedule.

CPP recommends members consider purchasing the entire allocated amount of Pentacel® for your practice each month in order to maintain your level of allocation throughout the entire period of constrained supply.

Price Increases – Sanofi Pasteur has announced price increases to many of their vaccines.

  • The new pricing for Adacel®, Diphtheria and Tetanus, Tenivac®, Tubersol®, Imogam® Rabies HT, Typhim Vi® and YF-Vax® will go into effect January 1, 2016.
  • Due to the supply issue mentioned above, the new pricing for Pentacel®, Daptacel®, IPOL®, and ActHIB® will be delayed and will go into effect July 1, 2016.

If you have any questions, please contact your Sanofi Pasteur representative or the CPP office at 614-722-2145.